Company / Cash & Equivalents
BioNexus Gene Lab Corp Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$2.5M
FY2025
5-year range
$2.1M / $2.9M
FY2021-FY2025
Trend
-13.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 5 years, ranging from $859,076 in FY2019 to $3M in FY2024.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -2.3%.
Improved from $2M to $2M over the past 4 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -2.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -2.3%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 13.9% year-over-year.
- Peak cash & equivalents was recorded in FY2024.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.5M | -13.9% |
| FY2024 | $2.9M | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $2.1M | -23.8% |
| FY2020 | $2.8M | +224.5% |
| FY2019 | $859.1K | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026